First Safety Study in Humans of a Single Dose of CPG 52364

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy Volunteers

In brief

Determine the safety and tolerability of the study drug, CPG 52364, when given as liquid or capsule. Another purpose is to determine how the drug enters and leaves the blood stream and body tissues over time.

Key facts

Study ID

NCT00547014

Run by

Pfizer

People needed

61

Starts

2007-09-01

Expected to finish

2008-04-01

Last updated by the study team

2009-03-19

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Normal body mass index and weight
• No significant diseases in the medical history or clinically significant findings on physical exam, opthalmologic exam, clinical laboratory evaluations or 12-lead electrocardiogram

You may not qualify if…

• Current illness or history of medical condition affecting the body's function
• Use of any medication within 7 days, any immunosuppressive medication within 6 months, any investigational drug within 30 days or any vaccine or immunoglobulin within 90 days
• Use of any medications during the study
• Positive TB test
• Smoking within 6 months
• Pregnancy or risk of Pregnancy
• Alcohol or drug misuse within 60 days
• Sensitivity to quinazolines

Where it is running

• Pfizer Investigational Site — Overland Park, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.